ERBB2 and breast cancer: International guidelines for the treatment of metastatic HR+/HER2(−) breast cancer recommend chemotherapy or hormone therapy as the first therapeutic choice for most patients, either as a single agent or in combination with a CDK4/6 inhibitor [9, 10].